Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Am J Phys Med Rehabil. 2017 Jun;96(6):408–416. doi: 10.1097/PHM.0000000000000638

Table 2.

Estimates of Adjusted Logistic Regression Models with ADL/IADL stage association with those who had trouble getting health care in the last year.

Model adjusted with ADL stage Model adjusted with IADL stage
Variable odds ratios (95% CIs) P value odds ratios (95% CIs) P value
Functional Characteristic of Stage (reference: Stage 0) <.0001 <.0001
Stage I 1.53 (1.32–1.76) <.0001 1.32 (1.12–1.56) 0.001
Stage II 1.74 (1.45–2.08) <.0001 2.03 (1.69–2.44) <.0001
Stage III 2.47 (1.99–3.06) <.0001 2.05 (1.65–2.54) <.0001
Stage IV 2.86 (1.97–4.14) <.0001 2.64 (1.79–3.89) <.0001
Demographic
Age (reference: 65–74) <.0001 <.0001
<65 2.61 (2.24–3.03) <.0001 2.45 (2.08–2.88) <.0001
75–84 0.61 (0.51–0.73) <.0001 0.61 (0.51–0.73) <.0001
>=85 0.42 (0.32–0.54) <.0001 0.41 (0.32–0.53) <.0001
Gender (reference: female)
Male 0.93 (0.80–1.08) 0.32 0.94 (0.81–1.09) 0.40
Race/Ethnicity (reference: non-Hispanic white) 0.02 0.02
Hispanic 1.35 (1.05–1.75) 0.02 1.36 (1.06–1.76) 0.02
non-Hispanic Black 0.86 (0.68–1.09) 0.21 0.87 (0.69–1.10) 0.25
Other 1.34 (0.90–2.00) 0.16 1.32 (0.88–1.97) 0.18
Education (reference: High school diploma or above)
No high school diploma 0.96 (0.85–1.09) 0.56 0.96 (0.84–1.09) 0.51
Metropolitan Setting (reference: Nonmetropolitan)
Metropolitan 1.12 (0.90–1.40) 0.32 0.96 (0.84–1.09) 0.51
Duel Insurance (reference: Medicare only)
Medicare plus Medicaid 1.42 (1.19–1.68) <.0001 1.12 (0.90–1.40) 0.31
Living Arrangement (reference: With spouse) <.0001 <.0001
Retirement community 1.41 (1.10–1.82) 0.01 1.43 (1.11–1.84) 0.01
With children 1.49 (1.21–1.83) 0.0002 1.49 (1.21–1.83) 0.0002
With others 1.49 (1.18–1.87) 0.001 1.44 (1.14–1.81) 0.002
Alone 1.43 (1.22–1.68) <.0001 1.44 (1.23–1.68) <.0001
Proxy Responded (reference: Sample person responded)
Proxy responded 0.69 (0.53–0.89) 0.01 0.59 (0.44–0.79) 0.001
Medical and disability condition
Vision Impairment (reference: No)
Yes 1.75 (1.45–2.10) <.0001 1.73 (1.45–2.06) <.0001
Hearing Impairment (reference: No)
Yes 1.27 (1.05–1.55) 0.02 1.19 (0.96–1.47) 0.12
* Number of comorbidities 1.05 (1.01–1.09) 0.03 1.06 (1.02–1.10) 0.01
*

Number of comorbidities including: mental retardation, Alzheimer’s/dementia, mental/psychiatric disorder, hypertension, myocardial infarction, angina/chronic heart disease, other heart disease, stroke, diabetes mellitus, Parkinson’s disease, emphysema/asthma/chronic obstructive pulmonary disease, rheumatoid arthritis, non-rheumatoid arthritis, osteoporosis/soft bones, and other (non-skin) cancer.